CSL Limited Annual Report 2022/23 57 Plasma donors People who donate plasma at one of the 342 CSL Plasma centres around the world are the real heroes. They allow tens of thousands of people worldwide to live normal, healthy lives – despite being impacted by rare and serious medical conditions. As one of the world’s largest producers of plasma-derived therapies and a leader in plasma collection, CSL Plasma commits to excellence and innovation across the full cycle of plasma donation, from donor screening throughout the donation process and across plasma testing and logistics. About 15,000 CSL Plasma employees take responsibility for ensuring safe, quality plasma is available to be manufactured into life-saving therapies. CSL has strengthened and grown its plasma collection footprint to support a safe and positive donor experience, while providing a reliable plasma supply as the needs of patients who require these therapies have increased. Appropriate donor screening and safe, compliant and efficient plasma collection both remain integral to a continuous quality supply of the starting material for the manufacture of plasma-derived therapies. Not only does each CSL Plasma centre provide plasma as the foundation of life-saving and life-enhancing therapies, they also contribute positively to local communities, supporting donors and benefitting the surrounding area. For a third year, CSL Plasma provided vouchers to United States plasma donors for influenza vaccines at a local pharmacy at no cost during the United States autumn and winter seasons. A mature centre that has operated for more than three years provides approximately 50 jobs, of which a majority are full-time, and contributes nearly US$6 million per centre in employee payroll and donor payments. CSL Plasma began implementation of the new Rika Plasma Donation System in August 2022 as part of a limited market release at centres starting in the Denver area in the United States, with plans to continue rollout of the device to other United States locations. Developed by Terumo Blood and Cell Technologies, the Rika system achieved regulatory clearance with the US Food and Drug Administration (FDA) in March 2022. In May 2023, CSL began working with Terumo on the clinical trial to evaluate an investigational individualised nomogram; a nomogram is the target collection volume the device is approved to for each procedure. Upon regulatory clearance, the new nomogram can be used with the Rika system. The Rika system supports a safe, efficient and improved experience for plasma donors and an improved employee experience including the features detailed below. • It completes one plasma collection in 35 minutes or less on average. When considering prior average CSL Plasma donation times, this could represent a nearly 30% reduction in average donation time for donors. • There is not more than 200 millilitres of blood outside the donor’s body at one time. This is expected to improve the donor’s comfort during the donation and reduce occurrence of a red cell loss deferral. It is designed with an advanced user interface to guide CSL Plasma front-line operators, as well as status indicators that inform donors and employees of donation progress. CSL Plasma donor experience and profile The socio-demographic background of United States CSL Plasma donors remains diverse. Based on self-reported survey data administered through the newly deployed CSL Plasma mobile app (1 July 2022 to 30 June 2023), CSL Plasma donors provided details on their occupational status:* • 55% described themselves as working full-time. • 19% described themselves as unemployed, inclusive of full-time parents, donors who are not looking for work or the unemployed. • 15% described themselves as part-time. • 3% described themselves as students. • 8% described themselves as other (e.g. military, retired). Of those plasma donors surveyed, 94% are willing to donate again, and 91% of plasma donors are willing to refer a friend to donate plasma at their CSL Plasma centre.* 94% of plasma donors are willing to donate again* 91% of plasma donors are willing to refer a friend to donate plasma at their CSL Plasma centre* * Limited assurance by Ernst & Young. CSL Plasma updated postdonation survey questions in September 2021 to use a Likert response scale from a prior yes or no answer. Data is based on 3.5 million survey responses. The percentages for willing to donate and refer a friend are comprised of total number of respondents who selected the top two (4 and 5) of five numbers on the Likert scale.
RkJQdWJsaXNoZXIy MjE2NDg3